Heymach JV, Mitsudomi T, Harpole D, Aperghis M, et al. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab+Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Clin Lung Cancer 2021 Oct 10. pii: S1525-7304(21)00265.
PMID: 34819266